Global Regulatory Update FDA, USP, EP and ICH Standards for Test Method Validation. Jane Weitzel
|
|
- Charlene Hamilton
- 5 years ago
- Views:
Transcription
1 Global Regulatory Update FDA, USP, EP and ICH Standards for Test Method Validation Jane Weitzel
2 Jane Weitzel Biosketch Jane Weitzel has been working in analytical chemistry for over 35 years for mining and pharmaceutical companies with the last 5 years at the director/associate director level. She is currently a consultant, auditor, and trainer. Jane has applied Quality Systems and statistical techniques, including the estimation and use of measurement uncertainty, in a wide variety of technical and scientific businesses. She has obtained the American Society for Quality Certification for both Quality Engineer and Quality Manager. She was pointed to the Chinese National Drug Reference Standards Committee and attended their inaugural meeting in Beijing for 2013 to 2016 For the cycle, Jane is a member of the USP Statistics Expert Committee and Expert Panel on Method Validation and Verification. mljweitzel@msn.com 2
3 Disclaimer This presentation reflects the speaker s perspective on this topic and does not necessarily represent the views of USP or any other organization. mljweitzel@msn.com 3
4 Abstract The ICH, USP and other global organizations, such as Eurachem, have provided guidances on method validation for many years. Understand the history of these guidances Learn how their similarities and differences Hear about the coming changes See how tools such as measurement uncertainty and QbD can be used today Look at Warning Letter Examples Prepare now for these changes 4
5 History of Method Validation Before 1970s, not much Errors, accuracy, precision 1970s papers published 1971 FDA approached (accuracy & precision) 1990s conferences and workshops EPA, AOAC, Eurachem 1995 USP <1225> 1999 release of standard ISO/IEC 17025: , 1996 & 2005 ICH A good discussion of history: Analytical Separation Science, Jared Anderson, Alain Berthod, Veronica Pino, Apryll M. Stalcup, mljweitzel@msn.com 5
6 Similarities & Differences Terminology Accuracy & trueness is a good example We need to define the terms we use and understand the differences Statistical approaches ISO, AOAC, USP, EP, IUPAC, FDA The good news: Becoming standardized mljweitzel@msn.com 6
7 Coming Changes Focus on good science Quality by Design Lifecycle approaches Statistical Techniques Bayesian Statistics Link to fitness for purpose Target Measurement Uncertainty Decision Rules 7
8 Good Science There are many types of pharmaceutical materials There are many types of analytical procedures There are many guidances There are many regulatory bodies Recent developments for analytical procedures include Good Science 8
9 Good Science Includes What Science Is and How and Why it Works Science power to probe and understand the behavior of nature on a level that allows us to predict with accuracy, if not control, the outcomes of events in the natural world. Science especially enhances our health, mljweitzel@msn.com 9
10 Scientific Method The scientific method, which underpins these achievements, can be summarized in one sentence, which is all about objectivity: Do whatever it takes to avoid fooling yourself into thinking something is true that is not, or that something is not true that is. 10
11 LOOK AT PHARMACEUTICAL INDUSTRY 11
12 Relevance of People & Concepts 12
13 Deming 13
14 Quality Total Quality Management Statistical Process Control Deming Juran Quality Control Quality Assurance American Society for Quality 14
15 Quality Revolution the Deming principle 8. Drive out fear, so that everyone may work effectively for the company the FDA is changing its regulatory approach to drive out fear Watch the Deming videos 15
16 EMA Mentions Deming 16
17 Sound Science Metrological approach to measurements Measurement uncertainty Target measurement uncertainty Completely characterises the variability 17
18 Scientifically Sound and Appropriate Laboratory controls shall include the establishment of scientifically sound and appropriate specifications, standards, sampling plans, and test procedures CFR has always required use of sound science: Decision rules, measurement uncertainty, risk and probability have been used in many scientific areas for many years. 18
19 21 CFR (d) (d) Acceptance criteria for the sampling and testing conducted by the quality control unit shall be adequate to assure that batches of drug products meet each appropriate specification and appropriate statistical quality control criteria as a condition for their approval and release. The statistical quality control criteria shall include appropriate acceptance levels and/or appropriate rejection levels. Decision Rule mljweitzel@msn.com 19
20 FDA Guidance The FDA Guidance discusses the role of the analytical procedure in the lifecycle of the product To meet its requirements Good science Metrology 20
21 Japan and QbD Pharmaceutical and Medical Devices Agency (PDMA) 21
22 Japan More sophisticated guidelines will be created Discusses the role of ICH in managing expectations for its responsibilities How ICH will remain relevant Will there be more emphasis on training? 22
23 Japan & ATP PF Article Translating the article on ATP 23
24 QbD The recognition that the current pharmaceutical industry's manufacturing performance was not as state of the art as other industries has been a key driver behind the increasing adoption of quality-by-design (QbD) concepts. The Role of Analytical Science in Implementing Quality by Design Mar 02, 2013 By Lucinda Buhse, Graham Cook, Moheb Nasr, Phil Nethercote, Siegfried Schmitt Pharmaceutical Technology Volume 37, Issue 3 mljweitzel@msn.com 24
25 ICH (International Council for Harmonization) 25
26 ICH Organizational Changes Held inaugural meeting Oct 27, 2015 The International Council for Harmonization (ICH) formerly the International Conference on Harmonization to establish a more stable operating structure. The committee is also now a legal entity under Swiss law. mljweitzel@msn.com 26
27 Global & Regulators The reforms will mean that ICH is a truly global initiative, expanding beyond the current ICH members. More involvement from regulators around the world is welcomed and expected, as they will be invited to join counterparts from Europe, Japan, USA, Canada and Switzerland as ICH regulatory members. mljweitzel@msn.com 27
28 Q12 EWG Q12 EWG Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management 28
29 Adoption of Step 4 Document 2Q 2017 mljweitzel@msn.com 29
30 ICH Q12 & Analytical Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Enable control strategy lifecycle (e.g., model maintenance, analytical lifecycle) 30
31 Q12 - Control & analytical Q12 will Support continual improvement of the manufacturing process and the control strategy which can result in decreased product variability and increased manufacturing efficiency mljweitzel@msn.com 31
32 ICH Q12 The efforts of the EWG are focused on lifecycle of the product from the perspective of the introduction of post-approval manufacturing changes. There is no specific focus on "lifecycle of methods" but up-to-date methodology is always encouraged; and so it would be desirable to lower the regulatory burden associated with making changes to methods during the product lifecycle. 32
33 ICH Q12 cont d. There has been discussion on which types of methods, and what aspects of methods, are part of the "established conditions" for the product approval; i.e., for what changes to methods used to analyse the product does one need to communicate directly with the regulatory agency (either requesting or notifying). There is some consideration that if the description of the analytical method can justifiably focus on the outcomes for the product, then many types of method changes would not need to be reported so long as the "outcome" does not change. The EWG is considering ways to try to illustrate this issue with examples of specific method parameters. 33
34 Q12 Point 1 1) for what changes to methods used to analyse the product does one need to communicate directly with the regulatory agency Briefly, what we are looking at is the use and estimate of measurement uncertainty which is extremely helpful in identifying these changes mljweitzel@msn.com 34
35 Q12 Point 2 2) There is some consideration that if the description of the analytical method can justifiably focus on the outcomes for the product, What we are looking at is the Target Measurement Uncertainty which clearly defines the link between the performance of the analytical procedure and its "fitness for purpose" which is the outcome for the product. mljweitzel@msn.com 35
36 Q2 Analytical Procedure Development and Revision of Q2 (R1) Analytical Validation Proposed 3 year timeline to review Include lifecycle Aligned with ICH Q8-Q12 mljweitzel@msn.com 36
37 ICH Future Proposed to address analytical requirements in detail about
38 Scientific Journals Fit for Intended Purpose Assays must therefore be suitable for the purpose of their respective applications. Harmonizing Best Practices in Bioanalytical Methods Citation: Tutunji L (2015) Harmonizing Best Practices in Bioanalytical Methods. MOJ Bioequiv Availab 1(1): DOI: / mojbb mljweitzel@msn.com 38
39 History Eurachem Eurachem was founded in 1989, and on the occasion of the tenth General Assembly, Alex Williams, the convenor of the initial meetings set up to consider establishing a forum for traceability in analytical chemistry in Europe. mljweitzel@msn.com 39
40 Eurachem Guides 40
41 Many Useful Guidelines Setting Target Measurement Uncertainty 41
42 New: Setting TMU Fit for Purpose is in the title 42
43 ISO Meeting internationally accepted criteria for validation and measurements of uncertainty as defined in ISO standards 9000 and will increase the likelihood of acceptance by international and national regulatory agencies. Validating Immunoassays Using the Fluorescence Polarization Assay for the Diagnosis of Brucellosis An Example and as an Application to ISO Standards 9000 and By David Gall and Klaus Nielsen 43
44 ISO Revision Includes: Decision rule TMU Risk Sampling Expected early
45 FDA Lab Quality Manual ORA labs have been accredited to ISO Recently added training information to the website Expanding to other FDA and State labs Food initiative, FSMA 45
46 FDA Policies and SOPs Includes Measurement Uncertainty (MU) 46
47 4. Background Every measurement or test has an error of measurement. If repeated, a test or measurement often gives a different result, even though it usually is very similar to the original result. Therefore, a test or measurement gives only an approximation of the true value of the quantity to be measured. A measurement or test is only complete if it includes the measurement uncertainty of the test. This can be thought of as a quantitative indication of the quality of the result. mljweitzel@msn.com 47
48 Added Training Useful reference on training in a laboratory mljweitzel@msn.com 48
49 Statistics 49
50 USP <1210> New proposed USP General Chapter <1210> Statistical Tools for Method Validation. This new proposed chapter, which was published in PF 42(5) [Sept-Oct 2016], will be a statistical companion chapter for USP General Chapter <1225> Validation of Compendial Procedures. mljweitzel@msn.com 50
51 USP PF The USP Pharmacopeia Forum (PF) Stimuli Articles and Proposed new general chapters articles are freely available from the USP.org website under the Pharmacopeia Forum (PF). You have to register once, but there is no charge 51
52 USP Stimuli Articles - USP.org Proposed New USP General Chapter: The Analytical Procedure Lifecycle <1220>;USP PF 42(6) Fitness for Use: Decision Rules and Target Measurement Uncertainty; USP PF 42(2) Analytical Target Profile: Structure and Application Throughout the Analytical Lifecycle; USP PF 42(5) Analytical Control Strategy; USP 42(5) Proposed new USP General Chapter <1210> Statistical Tools for Method Validation. This new proposed chapter, which was published in PF 42(5) [Sept-Oct 2016], will be a statistical companion chapter for USP General Chapter <1225>Validation of Compendial Procedures. Proposed New USP General Chapter: The Analytical Procedure Lifecycle 1220 USP PF 43(1) mljweitzel@msn.com 52
53 Law This bill requires the Food and Drug Administration to issue guidance that addresses using alternative statistical methods, including adaptive trial design and Bayesian methods, in clinical trials and in the development and review of drugs and biological products. 53
54 u definition Measurement uncertainty - The measurement of uncertainty is the parameter associated with the result of a measurement that characterized the dispersion of the values that could be reasonably attributed to the measurand. GUM & BIPM mljweitzel@msn.com 54
55 BIPM.org 55
56 Setting TMU This document discusses how to set a maximum admissible uncertainty, defined in the third edition of the International Vocabulary of Metrology as the target uncertainty, to check whether measurement quality quantified by the measurement uncertainty is fit for the intended purpose. mljweitzel@msn.com 56
57 Let s Look at FDA Guidance The FDA Guidance discusses the role of the analytical procedure in the lifecycle of the product To meet its requirements Good science Metrology mljweitzel@msn.com 57
58 Life Cycle Used 6 times Refers to the life cycle of the product Once an analytical procedure (including compendial methods) is successfully validated (or verified) and implemented, the procedure should be followed during the life cycle of the product to continually assure that it remains fit for its intended purpose. mljweitzel@msn.com 58
59 Continued Verification Over the life cycle of a product, new information and risk assessments (e.g., a better understanding of product CQAs or awareness of a new impurity) may warrant the development and validation of a new or alternative analytical method. mljweitzel@msn.com 59
60 Improvements in analytics In anticipation of life cycle changes in analytics, an appropriate number of retention samples should be maintained to allow for comparative studies. 60
61 Intended Purpose Intended purpose is mentioned 5 times Data must be available to establish that the analytical procedures used in testing meet proper standards of accuracy, sensitivity, specificity, and reproducibility and are suitable for their intended purpose. mljweitzel@msn.com 61
62 Stage 1, Design & Development Early in the development of a new analytical procedure, the choice of analytical instrumentation and methodology should be selected based on the intended purpose and scope of the analytical method. mljweitzel@msn.com 62
63 Stage 2 Analytical Procedure Qualification Analytical method validation is the process of demonstrating that an analytical procedure is suitable for its intended purpose. mljweitzel@msn.com 63
64 Stage 3 Continued Verification the procedure should be followed during the life cycle of the product to continually assure that it remains fit for its intended purpose. Trend analysis on method performance should be performed at regular intervals to evaluate the need to optimize the analytical procedure or to revalidate all or a part of the analytical procedure. mljweitzel@msn.com 64
65 Change The new method coupled with any additional control measures is equivalent or superior to the original method for the intended purpose. 65
66 Warning Letters 1 3. Your firm does not have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient and freedom from objectionable microorganisms, prior to release (21 CFR (a), (b)). mljweitzel@msn.com 66
67 Warning Letter 2 In your response to this letter, include: a list of the current quality control criteria and test methods you currently use to test each drug product batch prior to release. a thorough assessment to determine insufficiencies in chemical, physical, and microbiological specifications and analytical methods established for each of your drug products. Include a full remediation plan with appropriate specifications and analytical methods to be used for testing each batch of drug product. mljweitzel@msn.com 67
68 Warning Letter 3 1. Failure to ensure that test procedures are scientifically sound and appropriate to ensure that your API conform to established standards of quality and/or purity. mljweitzel@msn.com 68
69 Warning Letter 4 You have not shown how you will ensure that your test methods are appropriate to determine whether your API conform to established standards and specifications. Consequently, the summary data you provided does not demonstrate that previously released lots do not contain excessive levels of unknown impurities. mljweitzel@msn.com 69
70 Good Science The methodology and objective of the analytical procedures should be clearly defined and understood before initiating validation studies. This understanding is obtained from scientifically-based method development and optimization studies. 70
71 Lifecycle of Analytical Procedure Stage 1 Design Development & Understanding Stage 2 Performance Qualification Stage 3 Continued Performance Verification Session 1 Analytical Procedures and Method Validation Develop a Quality by Design (QbD) Approach for Analytical Method Development Session 6 Analytical Procedures and Method Validation Method Validation Characteristics through Statistical Analysis Approaches Session 8 - Investigating Laboratory OOS Test Results Manage Risk and Improve Efficiency in the Laboratory mljweitzel@msn.com 71
72 Career search Job descriptions are starting to include the knowledge and understanding of QbD, Life Cycle, and uncertainty. Proficiency with Quality by Design (QbD) concepts, statistical process control (SPC) and complex data analysis 72
73 Conclusion History we have come a long way New concepts meet the need MU, TMU, QbD, Life Cycle Regulatory bodies have adopted and continue to adopt these useful concepts Because They are based on sound science mljweitzel@msn.com 73
74 Trueness 74
Importance of ICH Guidance in Fulfilling Process Validation Requirements
Importance of ICH Guidance in Fulfilling Process Validation Requirements Presented by: Gamal Amer All rights reserved. Do not copy without permission. Principal 1 Premier Compliance Services, Inc. Process
More informationCMC Topics and PMDA s activities Yoshihiro Matsuda, Ph.D.
CMC Topics and PMDA s activities Yoshihiro Matsuda, Ph.D. Senior Scientist (for Quality) Pharmaceuticals and Medical Devices Agency (PMDA) MFDS Nov 11, 2016 1 Agenda Introduction of PMDA ICH Q12 QbD assessment
More informationQ8 and Q8 annex An industry Perspective
Workshop on Implementation of ICH Q8/Q9/Q10 and Other Quality Guidelines Beijing December 2008 Q8 and Q8 annex An industry Perspective Brian Withers, Abbott Laboratories, United Kingdom I attend this conference
More informationICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective
14 th DIA Japan Annual Meeting 2017 November 12-14, 2017 Tokyo Big Sight Ariake ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective Yasuhiro Kishioka, Ph.D. Principal Reviewer Office
More informationQbD Application in Japan: PMDA Perspective
CMC Strategy Forum Japan 2013 Hotel Okura, Tokyo, Japan, December 9 10, 2013 QbD Application in Japan: PMDA Perspective Yasuhiro Kishioka, PhD. Reviewer Office of Cellular and Tissue based Products Pharmaceuticals
More informationTerrence Tougas. Dennis Sandell
Terrence Tougas Boehringer Ingeheim, Ridgefield, CT Dennis Sandell S5 Consulting, Lund, Sweden (c) 2011 Sandell & Tougas 1 Transforming the general concept of Quality into objective, well defined and actionable
More informationQuality by Design. Innovate Design Development Create value. Correct definition of QbD and its relation to product and process development
Innovate Development Create value Quality by Correct definition of QbD and its relation to product and process development Dr John Loveluck 42 Technology Ltd +44 1480 302700 john.loveluck@42technology.com
More informationAnalytical Development Labs
Analytical Development Labs S-Matrix ADL Purdue Technology Center 5225 Exploration Drive Suite S-2357 Indianapolis, IN 46241 USA URL: www.smatrix.com Overview Major Pharmaceutical companies worldwide use
More informationProgressive Licensing and the Modernization of the Canadian Regulatory Framework
Progressive Licensing and the Modernization of the Canadian Regulatory Framework Workshop on Implementation of ICH Quality Guidelines Beijing, China 3-5 December, 2008 Mike Ward Health Canada 1 DISCLAIMER
More informationValue Paper. Are you PAT and QbD Ready? Get up to speed
Value Paper Are you PAT and QbD Ready? Get up to speed PAT and Quality-by-Design As PAT and Quality -by-design (QbD) become an integral part of the regulatory framework, automation group ABB argues more
More informationQuality Risk Management
Quality Risk Management Iron Chef Edition Keith D. Gibbs kage and sui generis Ninja Project Management My story shapes my perspective Bachelor of Science work in Earth Science with focus on Hydrogeology.
More informationPMDA perspective on Quality by Design for pharmaceutical products
PMDA perspective on Quality by Design for pharmaceutical products Junichi Fukuchi, Ph.D. Office of Cellular and Tissue-based Products Pharmaceuticals and Medical Devices Agency (PMDA) Annual conference
More informationTechnology Transfer Plays an Increasingly Important Role in Pharmaceutical Quality Systems
Technology Transfer Plays an Increasingly Important Role in Pharmaceutical Quality Systems A robust and secure manufactured product is the desired end result for pharmaceutical companies. Scale-up and
More informationJoint ILAC CIPM Communication regarding the. Accreditation of Calibration and Measurement Services. of National Metrology Institutes.
Joint ILAC CIPM Communication regarding the Accreditation of Calibration and Measurement Services of National Metrology Institutes 7 March 2012 Authorship This document was prepared by the International
More informationUSP Research & Innovation Program
USP Research & Innovation Program Ding Ming, Ph.D. Vice president, Research & Innovation United States Pharmacopeial Convention (USP) October 13, 2016 USP Programs and Products Impact Millions Worldwide
More informationFuture of Pharmaceutical Quality and the Path to Get There
Future of Pharmaceutical Quality and the Path to Get There Lawrence Yu, Ph.D. Deputy Director, Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research INTERPHEX 2018, April 18, 2018,
More informationICH Q8, 9 & 10 and the Impact on the QP
1 ICH Q8, 9 & 10 and the Impact on the QP Peter H. Gough David Begg Associates phg@david-begg-associates.com 2 A New Approach to Regulation Approach to the regulation of pharmaceuticals is undergoing a
More informationA BALANCING ACT: STREAMLINING METHOD TRANSFERS WITHOUT COMPROMISING COMPLIANCE OR SCIENCE JULIE FROST SENIOR SPECIALIST, QUALITY CONTROL
A BALANCING ACT: STREAMLINING METHOD TRANSFERS WITHOUT COMPROMISING COMPLIANCE OR SCIENCE JULIE FROST SENIOR SPECIALIST, QUALITY CONTROL PRESENTATION OUTLINE Introduction The Improved Comparative Study
More informationThe International Pharmacopoeia Overview
The International Pharmacopoeia Overview Prepared by Caroline Mendy Technical Officer - Quality Assurance and Safety: Medicines The International Pharmacopoeia P Content & Scope WHO Expert Committee on
More informationOffice of Pharmaceutical Quality Key Quality Initiatives
Office of Pharmaceutical Quality Key Quality Initiatives Ashley B. Boam, MSBE Director Office of Policy for Pharmaceutical Quality Office of Pharmaceutical Quality Center for Drug Evaluation and Research
More informationGlobal Harmonization Task Force
Global Harmonization Task Force How to minimize risks without constraining innovation and harming free trade The role of international standards And their application at regional and national levels Cornelis
More informationSTRATEGIES FOR SUCCESSFUL SCALE-UP USING QUALITY BY DESIGN
STRATEGIES FOR SUCCESSFUL SCALE-UP USING QUALITY BY DESIGN CHRISTOPHER J POTTER ISPE ADVISOR AND CMC CONSULTANT 1 AGENDA Background ICH Guidelines Terms and Definitions Supporting Information ISPE publications
More informationCurrent Status and Challenges of Bilateral/Multilateral Meetings
Current Status and Challenges of Bilateral/Multilateral Meetings Junko Sato, PhD International Liaison Officer PMDA 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The views and
More informationG9 - Engineering Council AHEP Competencies for IEng and CEng
G9 - Career Learning Assessment (CLA) is an alternative means of gaining Engineering Council Registration at either Incorporated Engineer (IEng) or Chartered Engineering (CEng) status. IAgrE encourages
More informationThe Process Analytical Technology Initiative: PAT and the Pharmacopeias
The Process Analytical Technology Initiative: PAT and the Pharmacopeias Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science CDER, FDA EDQM Spring Conference, Cannes, 3-43 4 May 2004
More informationCDER s Office of Pharmaceutical Quality (OPQ): Delivering on the 21 st Century Quality Goals
CDER s Office of Pharmaceutical Quality (OPQ): Delivering on the 21 st Century Quality Goals Lawrence X. Yu, Ph.D. Director (acting) Office of Pharmaceutical Science Food and Drug Administration IFPAC
More informationConformity assessment procedures for hip, knee and shoulder total joint replacements
1. INTRODUCTION NBRG 307/07 It is the primary purpose of this document to provide guidance to Manufacturers and Notified Bodies in dealing with the application of Directive 2005/50/EC on the reclassification
More informationEDQM Conference. Quality of Medicines in a Globalised World: Dreams and Reality
EDQM Conference Quality of Medicines in a Globalised World: Dreams and Reality 14-15 October 2010 Prague, Czech Republic 2010 EDQM, Council of Europe, All rights reserved Plenary Session Dr Moheb M. Nasr
More informationPDA 71 Years of Connecting People, Science and Regulation
PDA 71 Years of Connecting People, Science and Regulation 1 I m happy to be here. Bom Dia. Estou feliz por estar aqui. Richard M. Johnson PDA President & CEO since 2009 38 years experience in US and International
More informationDesignated Institutes participating in the CIPM MRA
Designated Institutes participating in the CIPM MRA Expectations and nomination form Version 1.2 Contents 1. Introduction... 1 2. Designated Institute in Appendix A of the KCDB... 2 2.1. Designation of
More informationSoftware as a Medical Device (SaMD)
Software as a Medical Device () Working Group Status Application of Clinical Evaluation Working Group Chair: Bakul Patel Center for Devices and Radiological Health US Food and Drug Administration NWIE
More informationClaudio Pincus, President, The Quantic Group R. Owen Richards, President, Quantic Regulatory Services Daniel Pincus, Consultant, The Quantic Group
FDA Compliance and Regulatory Symposium Understanding the FDA s Latest cgmp Guidances: Opportunities and Pitfalls Claudio Pincus, President, The Group R. Owen Richards, President, Regulatory Services Daniel
More informationTraining Prospectus Public Course Dates
Training Prospectus 2018 Public Course Dates Assuring Compliance in Life Science Operating extensively within the global pharmaceutical, biotech, medical device and related healthcare industries, the Honeyman
More informationQuality by Design, Clinical Relevance & Lifecycle Considerations
Quality by Design, Clinical Relevance & Lifecycle Considerations Robert Iser Acting Director Office of Process & Facilities / OPQ / CDER IFPAC 2016 1 FDA Quality Related Guidance and Initiatives Initiatives
More informationILNAS-EN 14136: /2004
05/2004 National Foreword This European Standard EN 14136:2004 was adopted as Luxembourgish Standard in May 2004. Every interested party, which is member of an organization based in Luxembourg, can participate
More information2-5 Frequency Calibration
2-5 Frequency SAITO Haruo, IWAMA Tsukasa, TSUCHIYA Shigeru, and KOYAMA Yasuhiro The Japan Standard Time (JST) and the Coordinated Universal Time (UTC(NICT)), which are constructed by National Institute
More informationImplementing Quality Systems
Implementing Quality Systems CGMP By The Sea August 29, 2006 Chris Joneckis, Ph.D. Senior Advisor For CMC Issues Center For Biologics Evaluation And Research Add FDA Bar and Presentation Overview Driving
More informationWHO Regulatory Systems Strengthening Program
WHO Regulatory Systems Strengthening Program MVP RHT RSS CRS www.who.int Minimal capacity met Eligibility for vaccine PQ WHO listed NRAs WHO NRA 5 step capacity building Development of NRA benchmarking
More informationUpdate on Lessons Learned from the EMA-FDA QbD Pilot
Update on Lessons Learned from the EMA-FDA QbD Pilot IFPAC 2014 Annual Meeting 22 January 2014 Sharmista Chatterjee, Ph.D. CMC Lead for QbD, ONDQA/OPS/CDER/FDA Background One of the projected outcomes
More informationEU GMP Evolution or Revolution Scope and drivers for EU GMP changes. August Gordon Farquharson
EU GMP Evolution or Revolution Scope and drivers for EU GMP changes August 2015 Gordon Farquharson EU & PIC/S Harmonisation at IWG level now Slide 2 PharmOut 2015 EU & PIC/S Harmonisation (1) What does
More informationPRIMATECH WHITE PAPER COMPARISON OF FIRST AND SECOND EDITIONS OF HAZOP APPLICATION GUIDE, IEC 61882: A PROCESS SAFETY PERSPECTIVE
PRIMATECH WHITE PAPER COMPARISON OF FIRST AND SECOND EDITIONS OF HAZOP APPLICATION GUIDE, IEC 61882: A PROCESS SAFETY PERSPECTIVE Summary Modifications made to IEC 61882 in the second edition have been
More informationQuality assurance in the supply chain for pharmaceuticals from the WHO perspective
1 Quality assurance in the supply chain for pharmaceuticals from the WHO perspective Dr Sabine Kopp Quality Assurance and Safety: Medicines Medicines Policy and Standards World Health Organization Presentation
More informationAnalytical Methods and Sampling in the New Manufacturing Paradigm a Regulatory Perspective
Analytical Methods and Sampling in the New Manufacturing Paradigm a Regulatory Perspective Dr. Øyvind Holte Norwegian Medicines Agency EMA PAT team/ EDQM PAT working party 15 October, 2014, Heidelberg
More informationInternational Journal of Pharma and Bio Sciences PROCESS ANALYTICAL TECHNOLOGY IMPLEMENTATION- PROGRESSION FOR A PHARMACEUTICAL INDUSTRY ABSTRACT
Research Article Analytical Chemistry International Journal of Pharma and Bio Sciences ISSN 0975-6299 PROCESS ANALYTICAL TECHNOLOGY IMPLEMENTATION- PROGRESSION FOR A PHARMACEUTICAL INDUSTRY SARAVANA KUMAR.V
More informationLatin-American non-state actor dialogue on Article 6 of the Paris Agreement
Latin-American non-state actor dialogue on Article 6 of the Paris Agreement Summary Report Organized by: Regional Collaboration Centre (RCC), Bogota 14 July 2016 Supported by: Background The Latin-American
More informationTGA Discussion Paper 3D Printing Technology in the Medical Device Field Australian Regulatory Considerations
TGA Discussion Paper 3D Printing Technology in the Medical Device Field Australian Regulatory Considerations MTAA Response - October 2017 October 2017 Australian Regulatory Considerations Page 1 of 7 Level
More informationVENUE. 2 DAY WORKSHOP On FDA Penalties for Regulatory Non-Compliance in the Pharmaceuticals Industry in Review , JAN San Diego CA
WORLD COMPLIANCE SEMINARS SPEAKER:- BRIAN G. NADEL President of Brian G. Nadel, GMP Consulting, LLC. 2 DAY WORKSHOP On FDA Penalties for Regulatory Non-Compliance in the Pharmaceuticals Industry - 2017
More informationFDA s Evolving Approach to Pharmaceutical Quality
FDA s Evolving Approach to Pharmaceutical Quality Lawrence Yu, Ph.D. Deputy Director, Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research 10th Annual FDA Inspections Summit Nov.
More informationPROGRAM OBJECTIVES-M.PHARM (PHARMACEUTICAL ANALYSIS)
PROGRAM OBJECTIVES-M.PHARM (PHARMACEUTICAL ANALYSIS) The Post-Graduates will acquire adequate scientific information regarding basic principles of Pharmaceutics including Cosmetology, Specialized drug
More information2008 Course Programs Schedule
2008 Course Programs Schedule Basic Laboratory Safety Laboratory Safety Biostatistics for the Non-Statistician - Basic Applied cgmps for Pharmaceutical and Allied Industries Good Clinical Practices (GCP)
More informationAN ANALYSIS OF THE METROLOGY TECHNIQUES TO IMPROVE QUALITY AND ACCURACY
AN ANALYSIS OF THE METROLOGY TECHNIQUES TO IMPROVE QUALITY AND ACCURACY Numan M. Durakbasa 1, Gökcen Bas 2 1 Prof.Dr., Vienna University of Technology, AuM, numan.durakbasa@tuwien.ac.at 2 Dr.techn., Vienna
More informationScience and mathematics
Accreditation of HE Programmes (AHEP): Collated learning outcomes for six areas of learning Programmes accredited for IEng Engineering is underpinned by science and mathematics, and other associated disciplines,
More informationPROMOTING QUALITY AND STANDARDS
PROMOTING QUALITY AND STANDARDS 1 PROMOTING QUALITY AND STANDARDS Strengthen capacities of national and regional quality systems (i.e. metrology, standardization and accreditation) Build conformity assessment
More informationSoftware Measurement & Lessons from the Masters: Benefits for Industry
Software Measurement & Lessons from the Masters: Benefits for Industry Alain Abran École de Technologie Supérieure Université du Québec alain.abran@etsmtl.ca 1 Masters from the Past Egyptian Pyramids 2
More informationFiscal 2007 Environmental Technology Verification Pilot Program Implementation Guidelines
Fifth Edition Fiscal 2007 Environmental Technology Verification Pilot Program Implementation Guidelines April 2007 Ministry of the Environment, Japan First Edition: June 2003 Second Edition: May 2004 Third
More informationInternational Cooperation in Strengthening Nuclear Security Capacities within Public Company Nuclear Facilities of Serbia
International Conference on Physical Protection of Nuclear Material and Nuclear Facilities, Vienna, 13-17 November 2017 Background and Objectives Cooperation with US DoE, WINS and IAEA Current status Planed
More informationAPI hapis High Potency Active Pharmaceutical Ingredients. High Potency Active Pharmaceutical Ingredients. Innovation made. Easy.
API hapis High Potency Active Pharmaceutical Ingredients High Potency Active Pharmaceutical Ingredients Innovation made. Easy. 2 High Potency Active Pharmaceutical Ingredients High potency APIs are our
More informationQuality Systems, Accreditation and the Food Sector
Presentation Outline Quality Systems, Accreditation and the Food Sector David Galsworthy Head of Quality Systems Team Central Science Laboratory York, UK My background The Quality Standards Accreditation
More informationTraining. Education CALENDAR FEDEGARI TECH CENTERS DM#407036
2016 CALENDAR COLLABORATION IN THE LIFE SCIENCES WORLD Valued customer, The need to increase efficiency and reliability in pharmaceutical manufacturing presents firms with unique opportunities to develop
More informationISO/FDIS Requirements for Traceability of Values Assigned to IVD Calibrators and Controls: A Viewpoint from US Industry
ISO/FDIS 17511 - Requirements for Traceability of Values Assigned to IVD Calibrators and Controls: A Viewpoint from US Industry JCTLM, June 10, 2002 Neil Greenberg, PhD Representing ADVAMED Manager, Regulatory
More informationCapstone Design. The Law of Unintended Consequences
Capstone Design Societal Impact of Engineering II Societal Impact of Engineering II (1 of 12) The Law of Unintended Consequences No matter how good a proposed solution seems to be, it will have some unintended
More informationICH Q-IWG Integrated Training Programme
Implementation of ICH Q8, Q9, Q10 ICH Q-IWG Integrated Training Programme International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Disclaimer
More informationIssues in Emerging Health Technologies Bulletin Process
Issues in Emerging Health Technologies Bulletin Process Updated: April 2015 Version 1.0 REVISION HISTORY Periodically, this document will be revised as part of ongoing process improvement activities. The
More informationFrom API to Formulated Product
From API to Formulated Product Jean-Marie Geoffroy, PhD Director, Product Development Takeda Global Research & Development 675 N Field Drive Lake Forest, IL 60045 jean-marie.geoffroy@tgrd.com Acknowledgments
More informationFor the Malaysia Engineering Accreditation Council (EAC), the programme outcomes for the Master of Engineering (MEng) in Civil Engineering are:
Programme Outcomes The Civil Engineering department at the University of Nottingham, Malaysia considers and integrates the programme outcomes (POs) from both the Malaysia Engineering Accreditation Council
More informationLorenza Jachia Secretary, Working Party on Regulatory Cooperation and Standardization Policies, UN Economic Commission for Europe
The UNECE Sectoral Initiative on Environments Equipment for Explosive A global legislative framework for Explosion Protection The comprehensive approach of the UNECE Model L Regulation Lorenza Jachia Secretary,
More informationBureau International des Poids et Mesures. International Recognition of NMI Calibration and Measurement Capabilities: The CIPM MRA
Bureau International des Poids et Mesures International Recognition of NMI Calibration and Measurement Capabilities: The CIPM MRA Prof. Michael Kühne International School of Physics Enrico Fermi Metrology
More informationAgency Information Collection Activities; Proposed Collection; Comment Request; Good
This document is scheduled to be published in the Federal Register on 06/12/2014 and available online at http://federalregister.gov/a/2014-13787, and on FDsys.gov DEPARTMENT OF HEALTH AND HUMAN SERVICES
More informationOffice of Pharmaceutical Quality: Why, What, and How?
Office of Pharmaceutical Quality: Why, What, and How? Lawrence Yu, Ph.D. Deputy Director, Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research NIPTE Annual Scientific Conference
More informationNew Approaches to Safety and Risk Management
New Approaches to Safety and Risk Management 15 18 May 2011 The 3rd DIA China Annual Meeting, Bejjin, China Ayman Ayoub MD MSC (med) Safety Surveillance & Risk Management Pfizer Disclaimer The views/opinions
More informationEAB Engineering Accreditation Board
EAB Engineering Accreditation Board Appendix B: Specified Learning Outcomes Summary of Engineering Council Output Statements Specific Learning Outcomes Knowledge is information that can be recalled. Understanding
More informationSwissmedic, Swiss Agency for Therapeutic Products
PMDA International Forum, 8 February 2014 Swissmedic, Swiss Agency for Therapeutic Products Jürg H. Schnetzer, Executive Director Grüezi. Bonjour. Buongiorno. Allegra. 2 Overview Swissmedic Introduction
More informationGuidance for Industry
Guidance for Industry Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP U.S. Department of Health and Human Services Food and Drug Administration Center for Drug
More informationAPMP GUIDELINES FOR ACCEPTING A QUALITY SYSTEM(V.2.0 WD2) approved on July 2010
APMP GUIDELINES FOR ACCEPTING A QUALITY SYSTEM(V.2.0 WD2) approved on July 2010 The CIPM global mutual recognition arrangement (global MRA) requires national metrology institutes (NMIs) to have in place
More informationEDUCATION ON STANDARDS DEVELOPED BY A PUBLIC INSTITUTION OF BRAZIL TO PROMOTE COMPETITIVENESS OF INDUSTRY
EDUCATION ON STANDARDS DEVELOPED BY A PUBLIC INSTITUTION OF BRAZIL TO PROMOTE COMPETITIVENESS OF INDUSTRY 8 th ICES CONFERENCE Industry Needs Standards. What Does Industry Expect from Standards Education?
More informationInnovative Approaches to Pharmaceutical Development and Manufacturing Seminar Series
CAMO European Pharmaceutical Seminars Jan/Feb 2009 Innovative Approaches to Pharmaceutical Development and Manufacturing Seminar Series The Increasing Need of Multivariate Analysis for Process Understanding
More informationSAUDI ARABIAN STANDARDS ORGANIZATION (SASO) TECHNICAL DIRECTIVE PART ONE: STANDARDIZATION AND RELATED ACTIVITIES GENERAL VOCABULARY
SAUDI ARABIAN STANDARDS ORGANIZATION (SASO) TECHNICAL DIRECTIVE PART ONE: STANDARDIZATION AND RELATED ACTIVITIES GENERAL VOCABULARY D8-19 7-2005 FOREWORD This Part of SASO s Technical Directives is Adopted
More informationSTATISTICAL METHODS FOR QUALITY IMPROVEMENT KUME
page 1 / 5 page 2 / 5 statistical methods for quality pdf What is Statistical Process Control (SPC)? Quality Glossary Definition: Statistical Process Control. Statistical process control (SPC) is defined
More informationInternational Conference on Pharmaceutical Research and Development June 06-07, 2018 Philadelphia, USA
International Conference on Pharmaceutical Research and Development,, https://research.pharmaceuticalconferences.com Invitation Dear Attendees, We are glad to announce the International Conference on Pharmaceutical
More informationGlobal GMP Harmonisation A Japanese Perspective
Global GMP Harmonisation A Japanese Perspective Yukio Hiyama, Ph.D. Chief, Third Section, Division of Drugs, National Institute of Health Sciences, The Ministry of Health Labour and Welfare, JAPAN ISPE
More informationDNVGL-CP-0338 Edition October 2015
CLASS PROGRAMME DNVGL-CP-0338 Edition October 2015 The electronic pdf version of this document, available free of charge from http://www.dnvgl.com, is the officially binding version. FOREWORD DNV GL class
More informationExpression Of Interest
Expression Of Interest Modelling Complex Warfighting Strategic Research Investment Joint & Operations Analysis Division, DST Points of Contact: Management and Administration: Annette McLeod and Ansonne
More informationChallenges of Implementation of ICH Q 8
Challenges of Implementation of ICH Q 8 A Regulatory Perspective Dr. Susanne Keitel BioKorea, Seoul, September 2007 Overview of the Presentation ICH Q 8: Background; EU Experience Design Space Associated
More informationE5 Implementation Working Group Questions & Answers (R1) Current version dated June 2, 2006
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE E5 Implementation Working Group & (R1) Current version dated June 2, 2006 ICH Secretariat,
More informationThe creation of the Emergency Preparedness and Response Expert Group (EPREG) which held its second meeting last month.
Remarks at SENIOR REGULATORS MEETING 19 September 2013 Good morning, Ladies and Gentlemen. I am pleased to welcome you to this meeting of Senior Regulators, which is an annual feature of the IAEA General
More informationAre there any new or emerging trends in technology that will impact the scope and work activities of the TC? Please describe briefly.
SMB/6478/SBP STRATEGIC BUSINESS PLAN (SBP) IEC/TC OR SC: SECRETARIAT: DATE: 87 UK 2016-12-12 A. STATE TITLE AND SCOPE OF TC Are there any new or emerging trends in technology that will impact the scope
More informationQuality by Design and OINDP. Today s Presentation
Quality by Design and OINDP Setting the Stage John C Berridge IPAC-RS September 2008 Today s Presentation QbD definition Setting the stage from an ICH perspective Future Opportunities 2 QbD Definition
More informationEDQM COUNCIL OF EUROPE CONFERENCE CERTIFICATION PROCEDURE : 20 YEARS OF EXPERIENCE March EDQM, Strasbourg, France ABSTRACTS
EDQM COUNCIL OF EUROPE CONFERENCE CERTIFICATION PROCEDURE 1992-2012: 20 YEARS OF EXPERIENCE 22-23 March 2012 EDQM, Strasbourg, France ABSTRACTS PLENARY SESSION, 22 March 2012 ABSTRACT 1.3 The Evolution
More informationOSIsoft. Users Conference 2013
OSIsoft. Users Conference 2013 Pharmaceutical and Life Sciences: Towards a Recipe Driven Company and the Critical Role of the Real Time Infrastructure Continuous Process Verification By: Martin Browning,
More informationThe Biological Weapons Convention and dual use life science research
The Biological Weapons Convention and dual use life science research Prepared by the Biological Weapons Convention Implementation Support Unit I. Summary 1. As the winner of a global essay competition
More informationProgress in FDA s Drug Product Quality Initiative. Janet Woodcock, M.D. November 13, 2003
Progress in FDA s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003 Impetus for Initiative: Modernization and continuous improvement in pharmaceutical manufacturing sector slow compared
More informationNOTE BY THE DIRECTOR GENERAL STATUS OF THE FOLLOW-UP TO THE RECOMMENDATIONS ON SCIENCE AND TECHNOLOGY MADE TO THE THIRD REVIEW CONFERENCE
OPCW Executive Council Seventy-Seventh Session 7 10 October 2014 5 September 2014 Original: ENGLISH NOTE BY THE DIRECTOR GENERAL STATUS OF THE FOLLOW-UP TO THE RECOMMENDATIONS ON SCIENCE AND TECHNOLOGY
More informationA Brief Introduction to the Regulatory Environment of Medical Device Supervision. CFDA Department of Legal Affairs Liu Pei
A Brief Introduction to the Regulatory Environment of Medical Device Supervision CFDA Department of Legal Affairs Liu Pei Development Trend of Medical Device Industry Development Opportunities of Medical
More informationILAC input to CIPM MRA Review Workshop October 2015
ILAC input to CIPM MRA Review Workshop 13-14 October 2015 BIPM Sevres 13 October 2015 By Erik Oehlenschlaeger ILAC (DANAK) ILAC History ILAC first started as a conference in 1977 (Copenhagen) with the
More informationCENTER FOR DEVICES AND RADIOLOGICAL HEALTH. Notice to Industry Letters
CENTER FOR DEVICES AND RADIOLOGICAL HEALTH Standard Operating Procedure for Notice to Industry Letters PURPOSE This document describes the Center for Devices and Radiological Health s (CDRH s, or Center
More informationNew Certified Reference Materials for Chromatography
New Certified Reference Materials for Chromatography Dr. Frank Michel Frank.michel@sial.com sigma-aldrich.com/analytical 2012 Sigma-Aldrich Co. All rights reserved. Use of Certified Reference Materials
More informationRequirements in Other Countries PQRI+USP EI Workshop; Rockville, MD, Dr. Helmut Rockstroh
Requirements in Other Countries PQRI+USP EI Workshop; Rockville, MD, 2015 Dr. Helmut Rockstroh Overview Introduction - Scope Pharmacopoeial + HA Positions Examples / Case Studies Discussion 2 Introduction:
More informationBuilding Toward a Modern Pharmaceutical Manufacturing Sector: Encouraging Development and Adoption of Emerging Technology
Building Toward a Modern Pharmaceutical Manufacturing Sector: Encouraging Development and Adoption of Emerging Technology Sau (Larry) Lee, Ph.D. Associate Director for Science Office of Pharmaceutical
More informationthe SPD company Dr Clive Simon, Principal, The SPD Company.
the SPD company With decades of local and international experience at the coalface, The SPD Company s specialists have built a solid repertoire of in-depth technical knowledge within the highly-regulated
More informationThe Medical Device Regulation: Transitioning between old and new
Association of British Healthcare Industries The Medical Device Regulation: Transitioning between old and new www.abhi.org.uk www.bdia.org.uk Introduction In May 2017, the new Medical Device Regulation
More information